Clinical Trial · NCT04687969

Multimodal Machine Learning Characterization of Solid Tumors

Overview

This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)

Sponsor

Massachusetts General Hospital

Contacts

Ciprian Catana, MD, Ph.D (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04687969

Drug / Compound

DCFPyL

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Eligibility

Inclusion

Must have primary prostate cancer (e.g. adenocarcinoma of prostate) and deemed a candidate for radical prostatectomy as part of standard clinical care for Cohort A.
estimated or measured glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2 for repeated administrations.

Exclusion

Reduced renal function as determined by creatinine or GFR values defined above obtained within 30 days prior to registration
Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e. 50 millisievert in the prior 12 months)
Body weight of \> 300 lbs (weight limit of the MRI table)